Statin therapy increases vascular sensitivity to angiotensin II in hypercholesterolaemic patients

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 5, Issue 3, 2004, Pages 109-113

  Sim, Justein S N ^a   Dick, John B C ^a   Struthers, Allan D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Angiotensin; Hypercholesterolaemia; Statins

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CERIVASTATIN; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; DOXAZOSIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NORADRENALIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; VASOCONSTRICTOR AGENT;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HORMONE RESPONSE; HORMONE SENSITIVITY; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; MALE; MULTIVARIATE ANALYSIS OF VARIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; UPREGULATION; VASCULAR ENDOTHELIUM; VEIN OCCLUSION PLETHYSMOGRAPHY;

EID: 6444229160     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2004.026     Document Type: Article

References (28)

1. Vita JA, Treasure CB, Nabel EG et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990;8:491-7.
2. Raij L. Hypertension, endothelium, and cardiovascular risk factors. Am J Med 1991;90(suppl 2A):13S-18S.
3. Preik M, Kelm M, Rosen P,Tschope D, Strauer BE. Additive effect of coexistent type 2 diabetes and arterial hypertension on endothelial dysfunction in resistance arteries of human forearm vasculature. Angiology 2000;51:545-54.
4. Heitzer T,Yla-Herttuala S, Luoma J et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolaemia. Role of oxidized LDL. Circulation 1996;93:1346-53.
5. The Heart Outcomes Prevention Evaluation Study Investigators. Effect of an ACE inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145-53.
6. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327:669-77.
7. Pedersen TR and the Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
8. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301-07.
9. Zdrojewicz Z, Januszewski A, Zareba-Bogdal E, Karwacki J, Plamieniak Z. Activity of converting enzyme angiotensin I to angiotensin II in patients with diabetes type II. Pol Arch Med Wewn 1995; 93 305-13.
10. Walker WG. Relation of lipid abnormalities to progression of renal damage in essential hypertension, insulin dependent and non insulin dependent diabetes mellitus. Miner Electrolyte Metals 1993; 19 137-43.
11. Chobanian AV, Haudenschile CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidaemic rabbit. Hypertension 1990;15:327-31.
12. Lee AFC, Dick JBC, Bonnar CE, Struthers AD. Lisinopril improves arterial function in hypercholesterolaemia. Clin Sci 1999;96:441-8.
13. Diet FP, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996;94:2756-67.
14. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low density lipoprotein in vascular smooth muscle cells. Circulation 1997;95:473-8.
15. Keidar S, Kaplan M, Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arteriosclerosis Thromb Vasc Biol 1996; 16:97-105.
16. Nickenig G, Jung O, Strehlow K et al. Hypercholesterolaemia is associated with enhanced angiotensin AII, receptor expression. Am J Physiol 1997;72:H2701-H2707.
17. Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolaemia and systemic hypertension. Am J Cardiol 1995;75:582-6.
18. Davidson NC, Barr CS, Struthers AD. C-type natriuretic peptide: an endogenous inhibitor of vascular angiotensin-converting enzyme activity. Circulation 1996;93:1155-9.
19. Greenfield ADM, Paterson GC. Reactions of the blood vessels of the human forearm to increases in transmural pressure. J Physiol (Lond) 1954;125:508-24.
20. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100:2131-4.
21. Seeger H, Mueck AO, Lippert TH. Fluvastatin increases prostacyclin and decreases endothelin production by human umbilical vein endothelial cells. Int J Clin Pharmacol Ther 2000;38:270-2.
22. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998;101:2711-19.
23. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-35.
24. Mitani H, Bandoh T, Ishikawa J, Kimura M, Totsuka T, Hayashi S. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br J Pharmacol 1996;119:1269-75.
25. Wassmann S, Laufs U, Baumer AT et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolaemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450-7.
26. Cahill PA, Redmond EM, Foster C, Sitzmann JV. Nitric oxide regulates angiotensin II receptors in vascular smooth muscle cells. Dur J Pharmacol 1995;288:219-29.
27. Katugampola SD, Davenport AP. Changes in ET(A)-, AT1 and AT2-receptors in the phenotypically transformed intimal smooth muscle layer of human atherosclerotic coronary arteries. J Cardiovasc Pharmacol 2000;36(suppl 1):S395-S396.
28. Spieker LE, Corti R, Binggeli C, Luscher T, Noll G. Baroreceptor dysfunction induced by NO synthase inhibition in humans. J Am Coll Cardiol 2000;36:213-18.